Objective To compare the effect of gimeracil and oteracil porassium capsules ( S-1 ) combined with docetaxel and capecitabine combined with docetaxel in the treatment of metastatic breast cancer .Methods Ac-cording to the digital table ,88 patients with metastatic breast cancer were randomly divided into the observation group and control group ,44 cases in each group .The observation group received S-1 combined with docetaxel treatment ,the control group received capecitabine combined with docetaxel treatment .The total effective rate ,progression free surviv-al,quality of life and the incidence of adverse reactions were compared between the two groups .Results The total effective rate of the observation group was 75.00%,which was significantly higher than 38.64%of the control group (χ2 =2.199,P<0.05).The progression free survival time in the observation group was (10.53 ±3.21) months, which was significantly longer than (5.72 ±2.10)months in the control group(t=0.667,P<0.05).After 3 months of follow-up,the body,social support,psychological,spiritual and other 4 factor scores of patients in the observation group were better than those in the control group (t=2.885,2.326,3.379,5.503,all P<0.05),the quality of life greatly improved .Conclusion The clinical efficacy of S-1 combined with docetaxel in the treatment of metastatic breast cancer is exact ,adverse reactions can be tolerated ,it can be used as a new clinical scheme of chemotherapy for metastatic breast cancer .

Objective To investigate the clinical features and possible pathogenesis of Moyamoya disease combined with hyperthyroidism. Methods The clinical data of 10 cases Moyamoya disease combined with hyperthyroidism were retrospectively analyzed.Results Among 10 patients in this group, 1 patient was male and 9 patients were female.All the patients were presented as ischemic cerebrovascular disease.One patient was diagnosed by DSA, 4 patients was diagnosed by CTA, and 5 patients was diagnosed by MRA.Nine patients had bilateral lesions and 1 patient had unilateral lesions.Conclusions The routine screening of thyroid function should be performed for patients with Moyamoya disease, especially women.And people who affected stroke should test cerebral vascular to early prevention and avoid stroke.

Objective To investigate the effects of tacrolimus on the expression of SCF mRNA in keratinocytes and c-kit mRNA in melanoma cells.Methods Tacrolimus was used to treat cultured HaCaT keratinocytes and B16 melanoma cells for 48 hours.Subsequently,real-time fluorescence quantitative PCR was performed to determine the mRNA expression of SCF in HaCaT cells and of c-kit in B16 cells.Results A significant change was observed in the expression of SCF mRNA in HaCaT cells and c-kit mRNA in B16 cells treated with tacrolimus compared with untreated HaCaT cells and B16 cells,respectively (both P<0.05).Conclusion Tacrolimus can upregulate SCF mRNA expression in HaCaT cells and c-kit mRNA expression in R16 cells.

Objective To investigate the expression of thanatos-associated protein-8 (THAP-8) in ovarian cancer tissue,and explore its clinical significance.Methods A total of 86 patients with ovarian cancer were enrolled.The gene and protein expression of THAP-8 of the ovarian cancer tissue and adjacent tissue were detected by fluorescent quantitation polymerase chain reaction and immunohistochemistry.Results The gene expressions of THAP-8 of ovarian cancer tissue and adjacent tissue were 0.304 ± 0.104 and 0.615 ± 0.152.The protein expressions of THAP-8 in ovarian cancer tissue and adjacent tissue were 30.16 ± 12.34 and 67.34 ± 22.37.The gene and protein expressions of THAP-8 in ovarian cancer tissue were significantly lower than those in adjacent tissue (P＜ 0.01).The gene and protein expressions of THAP-8 in the low and middle degree of tumor differentiation of ovarian cancer tissue were significantly lower than those of the high degree of tumor differentiation of ovarian cancer tissue (0.216 ±0.085 vs.0.457 ±0.124 and 24.22 ± 9.21 vs.46.24 ± 17.52,P ＜ 0.01 or ＜ 0.05).The gene and protein expressions of THAP-8 in lymph node metastasis of ovarian cancer tissue were significantly lower than those of no lymph node metastasis of ovarian cancer tissue (0.247 ± 0.087 vs.0.476 ± 0.133 and 23.44 ± 8.57 vs.49.60 ± 18.35,P ＜ 0.01 or ＜0.05).The gene and protein expressions of THAP-8 in clinical TNM pathologic Ⅲ,Ⅳ stage of ovarian cancer tissue were significantly lower than those of Ⅰ,Ⅱ stage of ovarian cancer tissue (0.232 ± 0.114 vs.0.424 ±0.125 and 25.64 ±8.12 vs.44.78 ± 16.84,P ＜0.05).Conclusions The downregulation-expression of THAP-8 has a closed relationship with the development of ovarian cancer.The THAP-8 might be used as a potential marker to assess the degree of rumor grade and prognosis in ovarian cancer.

Purpose:The phase I study was conducted to evaluate the maximum tolerated dose (MTD) and toxicity of weekly administered docetaxel combined with cisplatin in patients with non-small cell lung cancer ( NSCLC ). The other objective was to measure the pharmacokinetic/dynamics (PK/PD).Methods:In the dose escalation study, 15 patients with unresectable and metastatic untreated NSCLC with performance status(0-1) were enrolled. Escalating doses of D 25 mg/m 2 (30 mg/m 2, 35 mg/m 2, 40 mg/m 2) on day 1, 8, 15 were given as a 30 min iv infusions and C 75 mg/m 2 30 min iv infusion after D on day 1 and the cycle was repeated every 4 weeks. Blood samples were drawn on day 1 and 15 in the first cycle to measure the PK. Dose limiting toxicity(DLT) was based on Cycle 1 and defined as any Grade 3 non-hematologic toxicity not declining to Grade 2 or less within 4 days or any Grade 4 toxicity. Results:Chemotherapy was repeated for at least two cyc1es every 28 days. All patients were assessable for toxicities. Although grade 3/4 neutropenia occurred, there were no significant modifications of chemotherapy schedule. One patient developed an infection (DLT). Non-hematological toxicities, including nausea/vomiting, a1opecia, fluid intension and asthenia were tolerable. Based on these data, the MTD has not yet reached up to dose level of docetaxel of 40mg/m 2 weekly given in combination with cisplatin 75mg/m 2 every 4 weeks at the fixed dose. The exposure to docetaxel after Ⅳ administration on day 1 in combination with cisplatin and on day 15 without cisplatin , increased proportional to the dose for the range 25 to 40 mg/m 2, as measured by Cmax and AUC. No statistically significant difference between clearance values was shown for the 4 dose levels. The pharmacokinetics of docetaxel was not influenced by the coadministration of cisplatin on day 1 as compared to day 15, as the CmaxN, AUCN and CL were not statistically significantly different on both days. Fourteen patients were eva1uab1e for response, five cases achieved partial response, and thus the overall response was 35.7%. 1, 2, and 3 year survivals were 73%, 27%, and 20%, respectively. Weekly administration of docetaxel at 35mg/m 2 (days 1, 8, l5) combined with cisplatin 75mg/m 2 (day 1) is recommended for phase Ⅱ studies. Conclusions:Using the weekly schedule, toxicity was mainly manifested by non-hematologic profile and was well tolerated. A phase Ⅱ study is currently ongoing with docetaxel 35mg/m 2 as the suggested dosage.

Purpose:To study the efficacy and safety of docetaxel administrated weekly plus cisplatin in the treatment for patients with advanced non-small-cell lung cancer (NSCLC). Methods:Thirty-six patients with stage ⅢB,stage Ⅳ not treated previously by chemotherapy,or recurrenct after operation NSCLC received intravenous infusions of docetaxel at 35mg/m 2 three consecutive weeks,followed by a week of rest;and intravenous infusions of cisplatin at 75 mg/m 2 every four weeks. Results:There were 12 partial responses for an objective response rate of 33 %. The median survival was 11.5 months (range 4-27 months),and the 1-year survival was 50%. Hematologic toxicities,which were mild,included grade Ⅲ/Ⅳ neutropenia in 22%. The common nonhematologic toxicities included grade 2-3 nausea and vomiting (39%) and grade 2-3 asthenia (36%). Conclusions:Consecutive weekly administrations of docetaxel for 3 weeks plus cisplatin produce minimal myelosuppression and shows activity in the treatment of patients without previous chemtherapy with advanced NSCLC.

Objective To discuss the technique and clinical efficacy of percutaneous vertebroplasty (PVP) in the treatment of vertebral malignant lesion.Methods PVP was performed in 13 patients (15 vertibrae) including metastasis in 11 and primary tumor in 2 cases,thoracic vertebrae involved in 6 cases and lumbar vertebrae involved in 7 cases.13 cases aged between 45 and 73,median age 59 years.Under C-arm fluoroscopic or CT monitoring,needle the puncture of the vertebral body was performed through the pedicle of vertebral arch using 11~13G,15 cm long needle.Omnipaque was injected into the vertebral body to understand the information of large drain veins,then 3~7 ml of polymethylmethacrylate (PMMA) bone cement mixture(with the ratio of powder/contrast agent as 3GA9552GA9551 )was injected.The patients were followed up for 6~12 months.Results The successful rate of puncture was 100%.76.9%(10/13) of patients get better in symptoms in 3 days after operation,pain relieved in 6 months was 69.2%(9/13),in one year was 54.5%(6/11).In followed up period,CT showed the PMMA distribution was good,the vertebral body had no compression,the patients had no serious complications.Conclusion PVP is an effective and safe method for malignant lesion of vertebral body in anti-pain,preventing the compression vertebral body and secondary paraplegia.

Objective To study CGRP,Ang Ⅱ and ET in healthy offsprings from different families history of essential hypertension. Methods Sixty healthy offsprings with or without a family history of essential hypertension were recruited and divided into two groups: (1) 30 from family with either one parent of essential hypertension; (2) 30 from family with both parents of essential hypertension; (3) control group,30 subjects from family with parents negative history.The levels of plasma CGRP,Ang Ⅱ and ET were determined by radioimmunoassay. Results The plasma levels of CGRP,Ang Ⅱ in one parent group were(28.3?10.4 pg/mL),(52.5?11.1 pg/mL) and (37.7?14.7 pg/mL),(58.4?9.1 pg/mL) in both parents group,which were increased significantly as compared with those in the control group (CGRP 19.9?10.5 pg/mL,Ang Ⅱ 45.3?9.9 pg/mL,P

Objective To observe the effect of sesamol on the hematopoietic system in mice exposed to 4 Gy irradiation. Method Twenty C 57 BL/6 mice were randomly divided into control group, sesamol group, irradiated group and irradiated+sesamol group (n=5). Mice of control and sesamol group received sham irradiation, and the rest exposed to 4 Gy total body irradiation, dose rate 1.01 Gy/min. Mice in sesamol group and irradiated+sesamol group received a dose of 10 mg/kg sesamol administered by gavage every day for 7 days after irradiation exposure. Mice of other two groups were treated with vehicle solution. After 4 Gy irradiation 7 day, the peripheral bloods were collected. The levels of colony forming units-granulocyte-macrophage (CFU-GM) were detected. Results Compared to irradiation group, the level of WBC、cell count of BMNCs and CFU-GM significantly decreased in the irradiated mice, decreased in the irradiated mice (P<0.05). Compared to irradiation group, cell count of BMNCs and CFU-GM in the irradiated+sesamol group increased significantly (P<0.05). Conclusion Sesamol has a certain impact on the radiation-induced changes in hematopoietic system. The mechanism need to be further explored.

Objective To evaluate the effects of tacrolimus on the secretion of IL-6 and sIL-2R as well as the expression of IL-6 and sIL-2R mRNA by lymphocytes.Methods Jurkat human lymphoma cells were cultured and treated with tacrolimus of different concentrations.Enzyme linked immunosorbent assay was performed to determine the levels of IL-6 and sIL-2R in the supernatant of Jurkat cells at 48 hours after treatment with tacrolimus of 0,10,102,103 and 104 nmol/L,and real time reverse transcription PCR to measure the expression of IL-6 mRNA and sIL-2R mRNA of Jurkat cells at 48 hours after treatment with tacrolimus of 102 nmol/L.Results Tacrolimus of 102 - 104 nmol/L could suppress the secretion of IL-6 and sIL-2R from Jurkat cells (all P＜ 0.05),with a more marked suppressing effect achieved by the use of tacrolimus at 103 - 104 nmol/L.The expressions of IL-6 and sIL-2R mRNA from Jurkat cells were downregulated by tacrolimus of 102 nmol/L (both P ＜ 0.05).Conclusion Tacrolimus at certain concentrations could downregulate the secretion of IL-6 and sIL-2R as well as the expression of IL-6 and sIL-2R mRNA by lymphocytes.